What: Isis Pharmaceuticals and Genzyme Corporation to present mipomersen Phase 3 data in HoFH during the American Heart Association's 2009 Scientific Sessions in Orlando, FL When: Tuesday, November 17, 2009, at 9:00 a.m. PT / 12:00 p.m. ET Where: www.isispharm.com or www.genzyme.com How: Live on the Internet. Simply log on to one of our Web sites listed above. Isis Contacts: Kristina Lemonidis (Investors) (760) 603-2490 Amy Blackley, Ph.D. (Media) (760) 603-2772 Genzyme Contacts: Leah Monteiro (Investors) (617) 768-6602 Erin Emlock (Media) (617) 768-6923
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 11,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion.
With many established products and services helping patients in approximately 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as cardiovascular disease, neurodegenerative diseases, and other areas of unmet medical need.
Genzyme's press releases and other company information are available at www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.
SOURCE Isis Pharmaceuticals, Inc.
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved